Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pridopidine (FR310826) 是多巴胺稳定剂,是一种低亲和力的多巴胺 D2 受体拮抗剂。它高亲和力作用于 sigma 1受体,Ki=70-80 nM,比其对 D2R 的亲和力高约 100 倍。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 233 | 现货 | ||
2 mg | ¥ 328 | 现货 | ||
5 mg | ¥ 536 | 现货 | ||
10 mg | ¥ 829 | 现货 | ||
25 mg | ¥ 1,590 | 现货 | ||
50 mg | ¥ 2,380 | 现货 | ||
100 mg | ¥ 3,550 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 517 | 现货 |
产品描述 | Pridopidine (FR310826), a dopamine (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. |
靶点活性 | σ1 receptor:70-80 nM (Ki) |
体内活性 | The actions of pridopidine were mediated by S1R and led to normalization of ER Ca2+ release, ER Ca2+ levels and spine SOC entry in YAC128 MSNs. This is a new potential mechanism of action for pridopidine, highlighting S1R as a potential target for HD therapy. Upregulation of striatal proteins that regulate calcium, including calbindin and homer1a, upon chronic therapy with pridopidine, may further contribute to long-term beneficial effects of pridopidine in HD[1]. |
动物实验 | Sprague Dawley rats (n = 6) were treated daily by oral gavage with pridopidine (60 mg/kg) over 10 days. Six control Sprague Dawley rats were vehicle-treated. On the 10th day, 90 min following the last drug administration, brains were removed and RNA was isolated from the striatum of each rat and was analyzed using Affymetrix Rat 230_2 arrays. The gene expression data from 12 striatum samples was RMA normalized with affy package v1.42.3 in R v3.1.2. Probesets were annotated . The limma package v3.18.13 in R v3.1.3 was used to test if relevant calcium-related genes were differentially expressed between the two groups of biological replicates and multiple hypothesis testing was corrected for using the Bonferroni correction. Limma employs an empirical Bayes method to moderate standard error . When a gene had multiple probesets, the probeset with the highest absolute value of fold change was reported[1]. |
别名 | ACR16, ASP2314, FR310826, 4-[3-(甲磺酰基)苯基]-1-丙基哌啶 |
分子量 | 281.41 |
分子式 | C15H23NO2S |
CAS No. | 346688-38-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (177.68 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.5535 mL | 17.7677 mL | 35.5353 mL | 88.8383 mL |
5 mM | 0.7107 mL | 3.5535 mL | 7.1071 mL | 17.7677 mL | |
10 mM | 0.3554 mL | 1.7768 mL | 3.5535 mL | 8.8838 mL | |
20 mM | 0.1777 mL | 0.8884 mL | 1.7768 mL | 4.4419 mL | |
50 mM | 0.0711 mL | 0.3554 mL | 0.7107 mL | 1.7768 mL | |
100 mM | 0.0355 mL | 0.1777 mL | 0.3554 mL | 0.8884 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Pridopidine 346688-38-8 GPCR/G Protein Neuroscience Dopamine Receptor inhibit FR-310826 ACR16 Inhibitor ASP2314 ACR-16 ASP-2314 FR 310826 ACR 16 ASP 2314 FR310826 4-[3-(甲磺酰基)苯基]-1-丙基哌啶 inhibitor